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Abstract
Purpose: To evaluate efficacy and toxicity clinical in the intensified treatment of locally advanced squamous cell
carcinoma of the head and neck (SCCHN) with the combination of chemotherapy, the EGFR antibody cetuximab,
and intensity-modulated radiation therapy (IMRT) in a concomitant boost concept.
Methods: REACH is a prospective, bi-centric phase II trial of carboplatin/5-FU and cetuximab weekly combined
with IMRT. Primary endpoint is locoregional control, secondary endpoints include acute radiation effects and
adverse events. Evaluation of disease response is carried out according to the Response Evaluation Criteria in Solid
Tumors (RECIST); toxicity is assessed using NCI CTC v 3.0.
Results: Treatment was tolerated moderately well, acneiforme erythema occurred in 74.1% (grade II/III), mucositis
grade III in 28.6%, and radiation dermatitis grade III in 14.3%. Higher-grade side-effects resolved quickly until the
first follow-up post treatment. Objective response rates were promising with 28.6% CR at first follow-up and 92.9%
thereafter.
Conclusion: The combination of standard carboplatin/5-FU and cetuximab is feasible and results in promising
objective response rates. The use of an IMRT concomitant boost is practicable in a routine clinical setting resulting
in only moderate overall toxicity of the regimen.
Trial Registration Number: ISRCTN87356938.
Keywords: Radiochemotherapy, Radioimmunotherapy, Cetuximab, IMRT, Concomitant boost, Squamous cell head
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Introduction
Long-term disease control for patients with advanced
squamous cell carcinoma of the head and neck (SCCHN)
is still challenging. For locally advanced or unresectable
SCCHN without evidence of distant metastases, com-
bined radiochemotherapy is the only curative treatment
possibility. In the MARCH meta-analysis, concurrent
chemoradiotherapy results in an absolute survival benefit
of 6.5% at 5 years with the most effective regimen being
simultaneous chemoradiation [1-3]. This effect is mainly
caused by an improved local control and only to a lesser
extent by reduction of distant metastases. In the
MARCH data, platin-based regimens were shown to have
the highest effect in concurrent chemoradiotherapy [1-3].
Intensified radiotherapy such as altered fractionation
schedules also lead to a significant improvement of local
control but also overall survival if radiation therapy is
performed as a single therapy modality with the highest
benefit in hyperfractionated radiotherapy schedules [4].
Adding chemotherapy to altered fractionation radiother-
apy also resulted in improved outcome [5].
While intensified treatment regimen - whether as inten-
sified chemoradiation or altered fractionation radiotherapy
- have been shown to improve outcome [4,6], it is a clini-
cal fact that a significant percentage of patients are not
able to receive their full planned course of treatment due
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any medium, provided the original work is properly cited.to excessive toxicity, hence the need arises to modify and
optimize these regimens.
Various options exist: first of all, the use of more tol-
erable chemotherapy combinations, second the integra-
tion of molecular targeted drugs and third the use of
modern concepts of radiotherapy.
Staar et al. combined carboplatin with 5-FU and hyper-
fractionated accelerated radiotherapy in a randomized
phase III trial [7] and presented comparable results to
studies based on cisplatin. The published acute and late
toxicity was moderate in this trial. Targeted therapy
approaches with the EGFR antibody cetuximab have
been found to potentiate the effects of chemotherapy and
radiotherapy in experimental systems, Bonner and co-
workers were the first to establish combined radioimmu-
notherapy for SCCHN in a definitive setting [8,9]. Overall
survival and local control were significantly improved in
the combination regimen as opposed to the radiother-
apy-alone arm. Moreover, no further severe side effects
were reported apart from acneiforme skin reactions and
a low rate of infusion reactions [8,9]. Retrospective com-
parison of the Bonner data with landmark radioche-
motherapy studies suggests comparable results could be
achieved with this new combination [10].
Modern radiotherapy techniques such as intensity-
modulated radiotherapy (IMRT) and image guidance
(IGRT) have rapidly found acceptance in the routine treat-
ment of SCCHN. Intensity-modulated radiotherapy
(IMRT) has been shown to reduce acute and late toxicity
[11] and prevent long-term sequelae such as higher-grade
xerostomia by improved normal tissue sparing and preser-
vation of saliva flow [12,13]. Improved normal tissue spar-
ing permits relative dose escalation to the tumor in order
to improve local control and patient outcome [14].
REACH combines all of these approaches: systemic
treatment is intensified by the combination of che-
motherapy and EGFR antibody treatment (carboplatin/
5-FU and cetuximab) while local treatment is intensified
by a concomitant boost concept in IMRT technique.
Aim of the trial is to evaluate disease control, toxicity,
and feasibility of this intensified triple-therapy.
Methods
Patients
Patients with pathologically confirmed, locally advanced
non-metastatic squamous cell cancer of oropharynx,
hypopharynx, or larynx were eligible for the trial. Age
between 18 and 70 years, Karnofsky performance score
of > 70%, and adequate bone marrow, liver, and renal
function were also required. Exclusion criteria were naso-
pharyngeal carcinoma, prior chemotherapy, radiotherapy,
or exposure to EGFR pathway targeting therapy [15].
Work-up included complete panendoscopy, diagnostic
CT scans of the neck and chest, abdominal ultrasound,
and bone scan. In the absence of contraindications, all
patients received diagnostic MRI scans for treatment
planning and follow-up.
The trial was reviewed and approved by the University
of Heidelberg Medical School Ethics Committee;
informed consent was obtained from all patients prior
to inclusion.
Immunotherapy
Patients received the loading dose cetuximab one week
prior to RT (d1) at the recommended dose of 400 mg/
m
2 body surface followed by weekly infusions with
250 mg/m
2. All patients received 8 mg dexamethasone
and 4 mg dimetinden prior to each application of cetux-
imab. Missed out doses of cetuximab during the treat-
ment course are to be omitted. Cetuximab-induced skin
reactions are treated according to standard in-house
protocols and recommendations of the vendor with
topic or systemic antibiotics as indicated.
Chemotherapy
Carboplatin and 5-FU are given on days 8-12 and 36-40
(corresponding to radiotherapy-week 1 and 5). Carbo-
platin is prescribed at 70 mg/m
2 body surface as a one-
hour intravenous infusion, 5-FU at 600 mg/m
2 of body
surface as continuous infusion over 23 hours. Patients
are provided with standard antiemetic prophylaxis and
hydration according to institutional protocols.
Treatment planning and radiotherapy
Patients are immobilized using individual thermoplastic
head masks incl. shoulder fixation (HeadStep
®,I T V ) ,
planning examinations include CT-scan and contrast
enhanced MRI for 3D image correlation. Target volumes
are delineated in accordance with current guidelines and
recommendations [16-18].
All patients are treated with inversely-planned inten-
sity-modulated radiotherapy (IMRT) either at a 6 MV
linear accelerator in step-and-shoot technique or at a
6 MV tomotherapy unit under regular image guidance.
A dose of 50.4 Gy in daily fractions of 1.8 Gy (Mon-
day to Friday) is prescribed to the neck (CTV 2). From
study day 29 onwards, patients receive an additional
fraction at 1.5 Gy per day in a classical concomitant
boost regimen [19,20] to a total dose of 69.9 Gy to the
primary tumor and involved lymph nodes (CTV 1).
There is at least a 6-h-interval between the two daily
fractions.
Follow-up
Regular follow up is carried out 6 weeks post treatment,
3 months (4-5 months post completion of therapy) there-
after, and then in 6 monthly intervals including fibreoptic
examination and local imaging with MRI. In the presence
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contrast-enhanced CT scans.
Study design and analysis
REACH is a prospective, bi-centric, single-arm phase II
trial of combined radiochemoimmunotherapy with
weekly cetuximab, carboplatin and 5-FU (according to
the Staar protocol [7]) and IMRT in a concomitant
boost concept. Planned accrual is 60 patients.
Primary endpoint of the trial is local-regional control
(LRC); secondary endpoints are disease-free survival
(DFS), progression-free survival (PFS), overall survival
(OS), acute and late radiation effects, adverse events.
Control and survival data are calculated from adminis-
tration of cetuximab loading dose.
Physical examination and monitoring of adverse events
as well as routine hematologic and chemical blood analy-
sis is performed weekly throughout the treatment period.
Toxicity is assessed using NCI CTC v 3.0.
Evaluation of disease response is carried out according
to the Response Evaluation Criteria in Solid Tumors
(RECIST) [21] 6 weeks, 4-5 months, 6-7 months post
completion of treatment and then in 6-monthly intervals.
Further details can be found in the published trial protocol
[15].
Results
Between August 2009 and March 2012, twenty-one
patients were accrued to the REACH trial. Three patients
subsequently had to be excluded from the trial: two
patients had to be excluded due to poor compliance prior
to treatment start, another patient developed an anaphy-
lactic reaction to the trial medication on first exposure to
cetuximab and had to discontinue treatment within the
trial. Eighteen patients with a median age of 57 years (43
- 69) are treated within the protocol, fourteen patients
have completed treatment. Most patients had very
advanced disease not accessible to surgical treatment.
Fifteen out of 18 patients were male, all patients had a
history of heavy smoking. Fourteen patients completed
trial treatment as scheduled. Median dose to the cervical
lymph nodes was 50 Gy (49 - 51), the primary and
involved lymph nodes received a median total dose of
70 Gy (69 - 74 Gy). Median follow-up from cetuximab
loading dose excluding patients still under treatment (n =
14) is 17.4 months (6.5 - 30 months). Baseline character-
istics are displayed in Table 1.
Treatment was generally tolerated well with the most
common side effects being the typical, cetuximab-
induced acneiforme skin rash, mucositis, dysphagia, der-
matitis, and xerostomia. No chemotherapy cycle had to
be postponed or dose-reduced due to toxicity, acneiforme
rash was mostly moderate and did not lead to treatment
interruptions or dose changes. Twelve out of 18 patients
received a prophylactic feeding tube prior to therapy
start, however, only one patient was feeding tube depen-
dent during therapy. A list of observed side effects can be
found in Table 2.
There were six serious adverse events, three events
were judged unrelated to the trial treatment: one patient
has deceased due to systemically progressive disease
(CTC °V), one patient was hospitalized for treatment of
tonsillitis (CTC °III) 6 months after completion of ther-
apy, and one patient developed septic shock of unknown
genesis more than 6 months post completion of therapy,
and had a protracted, complicated hospital stay. One
patient was diagnosed with an abdominal wall abscess
under therapy, which had also occurred several times in
the past prior to trial treatment; relatedness to the trial
medication is therefore questionable but cannot be
excluded. Another patient developed an iliac artery
embolism and consequently had to undergo surgery. This
patient did not have any history of embolic events, no
cardiac arrhythmias or any other predisposing factors.
Table 1 Patient baseline and treatment characteristics;
patients still under therapy are not included in follow-
up/outcome analysis
characteristic range
median age (years), n = 18 57 44 -
69
median follow-up (months), n = 14 excluding pts
under treatment
17.4 6.5 -
30
deceased (pts) 1
male (pts) 16
female (pts) 5
Site (n = 18)
palate (pts) 2
oropharynx 7
hypopharynx 6
larynx 3
Stage (n = 18)
T2 3
T3 8
T4 7
N0 2
N2b 4
N2c 11
N3 1
therapy (n = 14)
median dose (cervical lymph nodes)/Gy 50 49 -
51
median dose (primary and involved nodes)/Gy 20 19 -
24
median total dose/Gy 70 69 -
74
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therefore possible. There was one anaphylactic reaction
to cetuximab at first exposure leading to discontinuation
of trial treatment. All patients recovered from the adverse
events.
Acute toxicity commonly observed in patients receiving
chemoradiation is resolving rapidly so far, residual muco-
sitis on the first follow-up (6 weeks post treatment) was
seen in 7/14 patients. Dysphagia was generally resolving
fast, 3 patients so far had evidence of dysphagia at the
second follow-up. One patient with large mediastinal
lymph node metastasis was still feeding-tube dependent
though this is not attributable to study treatment. There
is no higher-grade xerostomia, no evidence of higher-
grade late effects have been found so far (Table 3).
Treatment response is promising, first follow-up con-
trols are available in 14 out of 18 patients treated within
t h ep r o t o c o l .F i g u r e s1 ,2 ,3 ,4s h o wap a t i e n tw i t ha
complete remission already at the first follow-up. While
4/14 patients showed complete remissions on their first
follow-up, 8/14 patients had a CR on their second follow-
up visit (approx. 4-5 months post completion of treat-
ment). There was no planned prophylactic neck dissec-
tion after completion of treatment, one patient only has
yet had to undergo neck dissection for residual nodal dis-
ease. Pathology of the neck dissection revealed no vital
tumour cells. Six patients underwent microlaryngoscopy
or panendoscopy and probe excision after a median of
5.5 months [2.9 - 26.3 months] post treatment. None of
the samples showed any evidence of malignancy. Two
patients only showed stable disease on their first follow-
up. One developed a CR on his next visit, the other also
had a distant disease progression and received palliative
chemotherapy. This patient has deceased six months post
completion of treatment. Only two further patients with
a complete remission at the primary site developed
Table 2 Treatment adverse events (n = 14 pts)
adevers events
(AEs), n = 14
severity (CTC v. 3) grade
I II III IV V
acneiforme skin rash 5 (35.7%) 9 (64.3%) 1 (7.1%)
conjunctivitis 1 (7.1%)
skin fissures 1 (7.1%) 1 (7.1%)
mucositis 2 (14.3%) 8 (57.1%) 4 (28.6%)
dysphagia 5 (35.7%) 7 (50%) 1 (7.1%)
weight loss 1 (7.1%) 1 (7.1%)
dermatitis 2 (14.3%) 6 (42.9%) 2 (14.3%)
xerostomia 8 (57.1%) 5 (35.7%)
laryngeal oedema 3 (21.4%)
anemia 1 (7.1%)
leukopenia 1 (7.1%)
thrombopenia 1 (7.1%)
fever 1 (7.1%) 1 (7.1%)
hyperkalaemia 1 (7.1%)
hypokalaemia 2 (14.3%)
hypomagnesiaemia 3 (21.4%)
nausea 5 (35.7%)
oedema 7 (50%)
diarrhoea 3 (21.4%)
constipation 5 (35.7%)
Serious adverse events (SAEs)
skin abscess 1 (7.1%)
arterial embolism 1 (7.1%)
septic shock 1 (7.1%)
anaphylactic reaction 1 (7.1%)
hospital admission due to tonsillitis 1 (7.1%)
death due to progressive metastatic disease 1 (7.1%)
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sis) after treatment, one received systemic chemotherapy
according to the EXTREME regimen [22], the other
received local irradiation for solitary osseous metastasis.
Both are stable without further treatment (Table 4).
Median progression-free survival (PFS) has therefore not
yet been reached, overall progression-free survival at one
year is currently 84.4% (Figure 5). Swallowing rehabilita-
tion was successful in 13 out of the 14 patients, one
Table 3 Resolution of treatment-related side effects on follow-up (n = 14)
typical side
effects
CTC
grade
end of treatment (N =
14)
6 weeks post completion of treatment,
N=1 4
4-5 months post completion of treatment,
N=1 4
mucositis I 2 (14.3%) 5 (35.7%) 3 (21.4%)
II 8 (57.1%%) 2 (14.3%)
III 4 (28.6%) 0
dermatitis I 2 (14.3%) 6 (42.9%)
II 6 (42.9%) 0
III 2 (14.3%) 0
acneiforme skin
rash
I 5 (35.7%) 1 (7.1%)
II 9 (64.3%) 0
III 1 (7.1%) 0
dysphagia I 5 (35.7%) 4 (28.6%)
II 7 (50%) 9 (64.3%) 3 (21.4%)
III 1 (7.1%) 1 (7.1%) 1 (7.1%)
xerostomia I 8 (57.1%) 9 (64.3%) 10 (71.4%)
II 5 (35.7%) 2 (14.3%) 1 (7.1%)
Figure 1 50 y old patient with oro-/hypopharyngeal carcinoma;
planning MRI.
Figure 2 50 y old patient with oro-/hypopharyngeal carcinoma;
planning CT.
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distant metastatic disease with a large mediastinal mass.
Discussion
REACH combines the use of modern radiotherapeutic
techniques (IMRT), altered fractionation (accelerated/
hyperfractionated treatment), and systemic agents (con-
comitant radiochemotherapy with carboplatin/5-FU and
the EGFR antibody cetuximab) in order to improve local
control and ultimately patient outcome.
While treatment intensity with both the use of radioche-
motherapy, immunotherapy, and concomitant boost is
high, protocol treatment is tolerated reasonably well and
without treatment delays. The combination of carboplatin
and 5-FU has been shown to achieve similar results as cis-
platin 100 mg/m
2 q3 weeks with a more favourable toxi-
city profile and subsequently higher patient compliance
[7]. Bone marrow toxicity with grade III and IV (2/14 pts,
14.3%) was rare in our data and not higher than in our
reference protocol [7]. Mucositis rates were moderate with
no grade IV mucositis and 85.7% mucositis grade II and
III. Observed mucositis rates are lower than in reported in
the standard chemotherapy protocol where 68% mucositis
grade III and IV were seen [7]. Mucositis rates in the land-
mark trials for definitive radiochemotherapy of locally
advanced SCCHN vary widely between 12.8 and 77%
grade III mucositis, most report rates roughly between 50
and 70% [7,23-27]. However, these trials mostly employed
conventional radiotherapy techniques as IMRT was not
the standard at the time, therefore our low mucositis rates
may be attributable to the use of IMRT in our trial. Recent
phase II trials also employing combined radiochemother-
apy regimen and IMRT also report a lower incidence of
grade III and grade IV mucositis between 29 and 38%
[28-30]. Also, the rates of severe dysphagia of one in 14
patients (7.1%) and dysphagia CTC grade II (50%) in
REACH is very low in comparison with rates published in
the large phase III trials (31 - 44% dysphagia CTC grade
III, [23,24,27]). Again, intensity-modulated radiotherapy
trials report lower rates of severe dysphagia between 7%
and 28% [28-30] supports the observation of the REACH
trial.
Addition of cetuximab to chemoradiation with carbopla-
tin/5-FU so far lead to a rather moderate, increased skin
toxicity: acneiforme rash CTC grade II/III was present in
10/14 patients (71.4%) and correlates well with the obser-
vations by Bonner and colleagues [8,9] using conventional
radiation techniques and 11 - 67% reported in the com-
bined regimen using IMRT [29-31]. No cetuximab-specific
exfoliations occurred so far. No grade IV and only one
Figure 3 50 y old patient with oro-/hypopharyngeal carcinoma;
complete remission 6 weeks post completion of therapy.
Figure 4 50 y old patient with oro-/hypopharyngeal carcinoma;
complete remission 4 months post completion of therapy.
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the REACH protocol suggesting that our standard skin
care protocols in accordance with the recommendations
by the vendour help preventing major complications [32].
Response rates in the triple combination regimen are
promising so far: two patients only had stable disease on
their first follow-up after treatment corresponding to an
overall objective response rate of 85.7% (CR: 28.6%, PR:
57.1%). One patient with stable disease had developed
complete remission 4-5 months post completion of treat-
ment, the other patient with stable disease on the first fol-
low-up was diagnosed with distant metastases and has
deceased 6 months post completion of the REACH regi-
men. REACH response rates are in the range of rates
reported by other groups evaluating the combination of
chemotherapy and cetuximab in the definitive setting
[30,31,33] even though most of our patients had very
advanced disease and therefore represent a very negative
pre-selection. Interestingly though, theses protocols also
carried out planned neck dissections irrespective of remis-
sion status post completion of treatment. Notably, most
REACH patients showed partial remissions six weeks post
completion of therapy and had developed complete remis-
sions on the second follow-up three months afterwards
reflecting the fact that tumour response may take longer
than just 4-6 weeks after therapy. Our observation is sup-
ported by Beckmann and co-workers who saw only 16%
complete remissions at the first follow-up and 73% there-
after [34]. Prevalence and influence of HPV in our cohort
is currently under investigation.
We had six reported serious adverse events, for three of
them there is (anaphylactic reaction) or may be a rela-
tionship to the trial medication (abdominal wall abscess,
arterial embolism), all of these patients recovered
uneventfully from the adverse event, hence discontinua-
tion of the trial was not warranted.
So far, five phase II trials using chemotherapy, cetuxi-
mab and mostly IMRT are reported. Apart from Pfister
et al., all of them were completed as scheduled and did
not observe any unexpected toxicity [28-30,33], hence
the combination of chemotherapy, cetuximab, and mod-
ern radiotherapy techniques seems feasible and the use of
IMRT in a standard concomitant boost concept to
reduce overall treatment time and reduce tumor cell
repopulation [4,6,19] is practicable. Long-expected
results of the randomized RTOG 0522 phase III trial
comparing radiochemotheray +/- cetuximab have
recently been presented: so far, there is no significant dif-
ference between the two treatment arms could be found
with regard to progression-free survival and overall survi-
val. There seems to be a trend toward higher distant-
metastasis-free survival in the experimental arm (radio-
chemoimmunotherapy). Many patients have not yet even
reached median follow-up, subgroup analyses regarding
the influence of radiotherapy technique (accelerated
radiotherapy (3D) vs IMRT) has not yet been published
and is yet unclear [35]. Therefore it is too early to draw
any conclusions from this trial.
Unfortunately patient accrual to the REACH trial is
rather slow reflecting the fact that treatment of locally
advanced SCCHN is still primarily surgical in Germany.
However, functional outcome in of conservative treatment
strategies as reflected in the REACH trial is excellent,
apart from the patient with distant progressive disease and
mediastinal mass, treatment related dysphagia has rapidly
recovered post treatment. To date, there has been no case
of swallowing dysfunction.
Table 4 Treatment response
Local response 6 weeks post completion of treatment [pts,
(%)], N = 14
4-5 months post completion of treatment
[pts, (%)], N = 14
at time of analysis [pts,
(%)] N = 14
CR 4 (28.6%) 8 (57.1%) 13 (92.9%)
PR 8 (57.1%) 5 (35.7%) 0
SD 2 (14.3%) 1 (7.1%) 1(7.1%)
PD (locoregional) 0 0 0
PD (distant
metastases)
0 1 (7.1%) 3 (21.4%)
Figure 5 Overall progression-free survival (PFS) (n = 14 pts).
PFS at 1 year: 84.4%; PFS at 2 years 63.3%.
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The combination of our standard radiochemotherapy regi-
men with carboplatin/5-FU and cetuximab is feasible
resulting in promising objective response rates. Also the
use of a classical concomitant boost concept in intensity-
modulated technique has been shown to be practicable in
a routine clinical setting resulting in only moderate overall
toxicity of the regimen. However, patient accrual needs to
be improved.
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